Repurposed benzimidazole anthelmintics—most notably mebendazole (MBZ), albendazole (ABZ), flubendazole (FBZ), and fenbendazole—have been extensively evaluated across a broad spectrum of human cancers. These compounds disrupt tubulin polymerization, inhibit tumor angiogenesis, block glucose uptake, suppress cancer stem-like cell properties, and induce apoptosis across numerous malignant cell types. This article discusses In Vitro and In Vivo Preclinical Testing (Lab & Animal).
Primary Human Cancer Types Targeted and Preclinical Evidence
1. Brain and Central Nervous System (CNS) Cancers
Targeted Types: Glioblastoma multiforme (GBM), medulloblastoma, high-grade gliomas, meningioma, and pediatric brain tumors.
Preclinical Testing (Lab & Animal):
In Vitro: MBZ and FBZ significantly inhibit tubulin polymerization and decrease cell viability in human glioblastoma lines (such as the temozolomide-resistant stem-like line 060919) and pediatric medulloblastoma lines across Sonic Hedgehog (SHH) and MYC-amplified subgroups.
In Vivo: MBZ crosses the blood–brain barrier. In intracranial syngeneic mouse glioma (GL261) and human xenograft models, MBZ significantly prolongs mean survival both as a monotherapy and in combination with temozolomide. In orthotopic rodent models of medulloblastoma and intracranial meningioma, MBZ inhibits tumor angiogenesis, reduces tumor burden, and enhances radiation therapy.
2. Gastrointestinal and Digestive Cancers
Targeted Types: Colorectal cancer (CRC), gastric cancer, pancreatic cancer, hepatocellular carcinoma (HCC), cholangiocarcinoma, and paraganglioma.
Preclinical Testing (Lab & Animal):
In Vitro: MBZ, ABZ, FBZ, oxibendazole, and parbendazole display potent nanomolar-to-micromolar cytotoxicity in colorectal (HT29, SW480, HCT116), gastric (AGP01), pancreatic (AsPC-1, BxPC-3), and patient-derived paraganglioma cell lines (PTJ64i, PTJ86i). MBZ induces apoptosis in cholangiocarcinoma cells via caspase-3 activation.
In Vivo: MBZ treatment causes marked volume and weight reduction (over 60%) in HT29 and SW480 CRC xenografts. In transgenic \(Apc^{Min/+}\) mouse models of intestinal polyposis, MBZ reduces tumor formation by 56% alone and by up to 90% in combination with sulindac. In murine hepatocellular carcinoma models, MBZ lowers serum ALT/AFP levels and increases sensitivity to sorafenib.
3. Thoracic Cancers (Non-Small Cell Lung Cancer - NSCLC)
Targeted Types: Non-small cell lung carcinoma (including A549, H129, and H460 cell lines).
Preclinical Testing (Lab & Animal):
In Vitro: MBZ depolymerizes tubulin, triggers G2/M mitotic arrest, upregulates p53 and p21, and activates caspase-mediated apoptosis in human NSCLC lines while sparing normal human fibroblasts and endothelial cells.
In Vivo: In H460 lung cancer mouse xenografts, oral MBZ leads to near-complete tumor growth arrest and a substantial reduction in tumor blood vessel density (neovascularization). In A549 xenograft models, MBZ inhibits lung metastatic colony formation by about 80%.
4. Breast Cancers
Targeted Types: Triple-Negative Breast Cancer (TNBC), HER2-positive breast cancer, and chemoresistant breast adenocarcinoma.
Preclinical Testing (Lab & Animal):
In Vitro: FBZ and MBZ target cancer stem-like cells (CSCs), induce double-strand DNA breaks, downregulate stemness markers (CD44/CD24, OCT4, SOX2, NANOG), and overcome trastuzumab resistance in HER2-positive cells.
In Vivo: MBZ acts as a potent radiosensitizer in TNBC mouse models, causing significant primary tumor delay and reduction of distant lung/liver metastases. Flubendazole suppresses tumor growth, angiogenesis, and metastatic spread in MDA-MB-231 and HER2+ JIMT-1 mouse xenografts.
5. Melanoma and Skin Cancers
Targeted Types: Refractory \(NRAS^{Q61K}\)-mutant melanoma, chemoresistant melanoma, and cutaneous squamous cell carcinoma.
Preclinical Testing (Lab & Animal):
In Vitro: MBZ induces apoptosis in chemoresistant melanoma cells by inactivating Bcl-2 and downregulating X-linked inhibitor of apoptosis (XIAP).
In Vivo: In melanoma mouse xenograft/allograft models, MBZ suppresses tumor growth by ~70%. Combining MBZ with the MEK inhibitor trametinib synergistically suppresses refractory \(NRAS\)-mutant melanoma tumors.
6. Hematological Malignancies
Targeted Types: Acute Myeloid Leukemia (AML), Multiple Myeloma, and Lymphoma.
Preclinical Testing (Lab & Animal):
In Vitro: MBZ induces degradation of the c-MYB oncogene and GLI transcription factors in AML cells, blocking leukemia colony formation while sparing normal CD34+ cord blood progenitor cells. Flubendazole inhibits microtubule function and induces apoptosis in multiple myeloma and leukemia lines.
In Vivo: In bioluminescent THP1 AML mouse xenografts, MBZ significantly retards leukemia progression and extends animal survival.
7. Endocrine and Urological Cancers
Targeted Types: Adrenocortical carcinoma, advanced thyroid cancer, and prostate cancer.
Preclinical Testing (Lab & Animal):
In Vitro: MBZ displays antiproliferative activity against adrenocortical, thyroid, and prostate cancer cell lines, and synergizes with docetaxel in prostate cancer.
In Vivo: MBZ inhibits growth in human adrenocortical carcinoma and thyroid cancer nude mouse xenografts while preventing distant lung metastases. (Note: Human case reports also documented 19 months of disease stabilization in a patient with metastatic adrenocortical carcinoma).
8. Head, Neck, and Gynecological Cancers
Targeted Types: Head and neck squamous cell carcinoma (HNSCC), oral carcinoma, and ovarian carcinoma.
Preclinical Testing (Lab & Animal):
In Vitro: MBZ enhances cisplatin-induced cell death in HNSCC. In oral squamous cell carcinoma, MBZ downregulates metastatic signaling enzymes including FAK, Rho-A, and Rac1.
In Vivo: Nanoparticle and cyclodextrin formulations of albendazole significantly reduce ascites accumulation, tumor weight, and VEGF expression in SK-OV-3/OVCAR-3 ovarian cancer mouse xenografts.
Summary of Preclinical Approaches
In Vitro Assays: Microtubule depolymerization/tubulin assays, IC50 cell viability panels (MTT/PRISM), cell cycle flow cytometry (G2/M arrest), apoptosis detection (caspase 3/7, Annexin V), wound-healing/migration assays, and mammosphere/colony formation assays for cancer stem cells.
In Vivo Animal Models: Mouse subcutaneous allografts and human cell line xenografts, orthotopic intracranial brain models (for GBM/medulloblastoma), genetically engineered mouse models (such as \(Apc^{Min/+}\) for polyposis), and tail-vein injection metastatic colony models.
Sources:
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., Papapetropoulos, S., Grossman, I., & Laifenfeld, D. (2018). Drug repurposing from the perspective of pharmaceutical companies. British Journal of Pharmacology, 175(2), 168–180. [suspicious link removed]
Source file:
repurpose-BPH-175-168.pdf
Durden, T. (2025, June 26). Cancer patients recover by taking repurposed anti-parasitic drugs. ZeroHedge (via The Epoch Times).
Source file:
Cancer Patients Recover By Taking Repurposed Anti-Parasitic Drugs _ ZeroHedge.pdf
Florio, R., Carradori, S., Veschi, S., Brocco, D., Di Genni, T., Cirilli, R., Casulli, A., Cama, A., & De Lellis, L. (2021). Screening of benzimidazole-based anthelmintics and their enantiomers as repurposed drug candidates in cancer therapy. Pharmaceuticals, 14(4), 372. [suspicious link removed]
Source file:
repurpose-pharmaceuticals-14-00372.pdf
Freeman, H. (2025, June 24). How 1 cancer survivor triggered interest in repurposed antiparasitic drugs. The Epoch Times.
Source file:
How 1 Cancer Survivor Triggered Interest in Repurposed Antiparasitic Drugs _ The Epoch Times.pdf
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., & Bresciani, R. (2019). Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers, 11(9), 1284. [suspicious link removed]
Source file:
----Mebendazole-Drug-Repurposing-Oncology.pdf
Hegazy, S. K., El-Azab, G. A., Zakaria, F., Mostafa, M. F., & El-Ghoneimy, R. A. (2022). Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sciences, 299, 120536. https://doi.org/10.1016/j.lfs.2022.120536
Source file:
Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer - ScienceDirect.pdf
Ioakeim-Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza-Pascual-Salcedo, M., Gimeno-Miguel, A., Orlando, V., González-Rubio, F., Fanlo-Villacampa, A., Lasala-Aza, C., & Ostasz, E. (2023). Drug repurposing in oncology: A systematic review of randomized controlled clinical trials. Cancers, 15(11), 2972. [suspicious link removed]
Source file:
Drug Repurposing in Oncology_ A Systematic Review of Randomized Controlled Clinical Trials.pdf
Khachigian, L. M. (2021). Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent. Cancer Letters, 522, 57–62. https://doi.org/10.1016/j.canlet.2021.09.013
Source file:
Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent - ScienceDirect.pdf
Larsen, A. R., Bai, R. Y., Chung, J. H., Borodovsky, A., Rudin, C. M., Riggins, G. J., & Bunz, F. (2015). Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Molecular Cancer Therapeutics, 14(1), 3–13. [suspicious link removed]
Source files:
----Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.pdf&---Repurposing-mebehndazdole.pdf
Meco, D., Attinà, G., Mastrangelo, S., Navarra, P., & Ruggiero, A. (2023). Emerging perspectives on the antiparasitic mebendazole as a repurposed drug for the treatment of brain cancers. International Journal of Molecular Sciences, 24(2), 1334. [suspicious link removed]
Source file:
Meco et al. - 2023 - Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Bra.pdf
Mohi-ud-din, R., Chawla, A., Sharma, P., Mir, P. A., Pottoo, F. H., Reiner, Ž., Reiner, I., Ateşşahin, D. A., Sharifi-Rad, J., Mir, R. H., & Calina, D. (2023). Repurposing approved non-oncology drugs for cancer therapy: A comprehensive review of mechanisms, efficacy, and clinical prospects. European Journal of Medical Research, 28(1), 345. [suspicious link removed]
Source file:
---11-Repurposing approved non-oncology drugs for cancer therapy_ a comprehensive review of mechanisms, efficacy, and clinical prospects.pdf
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020). Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects. Life Sciences, 258, 118189. https://doi.org/10.1016/j.lfs.2020.118189
Source file:
Drug repurposing and relabeling for cancer therapy_ Emerging benzimidazole antihelminthics with potent anticancer effects - ScienceDirect.pdf
Nowak-Sliwinska, P., Scapozza, L., & Ruiz i Altaba, A. (2019). Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1871(2), 434–454. https://doi.org/10.1016/j.bbcan.2019.04.005
Source file:
Drug repurposing in oncology_ Compounds, pathways, phenotypes and computational approaches for colorectal cancer - ScienceDirect.pdf
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. ecancermedicalscience, 8, 443. [suspicious link removed]
Source file:
----Repurposing Drugs in Oncology (ReDO)___mebendazole as an anti-cancer agent.pdf
Patil, V. M., Bhelekar, A., Menon, N., Bhattacharjee, A., Simha, V., Abhinav, R., Abhyankar, A., Sridhar, E., Mahajan, A., Puranik, A. D., Purandare, N., Janu, A., Ahuja, A., Krishnatry, R., Gupta, T., & Jalali, R. (2020). Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. Cancer Medicine, 9(13), 4676–4685. [suspicious link removed]
Source file:
--repurposing-mebendazole-recurrent-high-grade-glioma-10-1002-cam4-3094.pdf
Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., & Leung, H. Y. (2020). Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122(4), 517–527. [suspicious link removed]
Source file:
---Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment_.pdf
Simbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y. S., Fang, H. B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., Atkins, M. B., Byers, S. W., & Rosenthal, D. S. (2017). The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget, 8(8), 12576–12595. [suspicious link removed]
Source files:
---The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.pdf&repurposed-anthelmintic-mebendazole.pdf
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017). Drug repurposing in cancer. Pharmacological Research, 124, 74–91. https://doi.org/10.1016/j.phrs.2017.07.013
Source file:
Drug repurposing in cancer - ScienceDirect.pdf
Son, D. S., Lee, E. S., & Adunyah, S. E. (2020). The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immune Network, 20(4), e29. https://doi.org/10.4110/in.2020.20.e29
Source file:
---The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.pdf
Vaziri, S., Serak, J., & Wang, M. (2015). Repurposing mebendazole for the treatment of medulloblastoma. Neurosurgery, 76(2), N15–N16. [suspicious link removed]
Source files:
---repurposing_mebendazole_for_the_treatment_of.5.pdf&repurposing-mebendazole-for-the-treatment-of-medulloblastoma.pdf
Weth, F. R., Hoggarth, G. B., Weth, A. F., Paterson, E., White, M. P. J., Tan, S. T., Peng, L., & Gray, C. (2024). Unlocking hidden potential: Advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer, 130(5), 703–715. https://doi.org/10.1038/s41416-023-02502-9
Source file:
REPURPOSING--s41416-023-02502-9.pdf
Woollams, C. (2022, May 10). Repurposed, off-label drugs as new and effective cancer treatments: Top 25. CANCERactive.
Source file:
Repurposed, off-label drugs as new and effective cancer treatments_ Top 25 _ CANCERactive.pdf
Xia, Y., Sun, M., Huang, H., & Jin, W. L. (2024). Drug repurposing for cancer therapy. Signal Transduction and Targeted Therapy, 9(1), 92. https://doi.org/10.1038/s41392-024-01808-1
Source files:
2024-XiaDrugrepurposingforcancertherapy.pdf&REPURPOSING--s41392-024-01808-1.pdf
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020). Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy, 5(1), 113. [suspicious link removed]
Source file:
DRUG-REPURPOSING--s41392-020-00213-8.pdf